查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1747747

全球转录组学技术市场

Transcriptomics Technologies
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 166 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球转录组技术市场规模将达到 120 亿美元

全球转录组学技术市场规模预计在2024年为79亿美元，预计到2030年将达到120亿美元，2024年至2030年期间的复合年增长率为7.2%。转录组学耗材是本报告分析的细分市场之一，预计其复合年增长率为5.3%，到分析期结束时规模将达到47亿美元。转录组学仪器细分市场在分析期间的复合年增长率预计为9.2%。

美国市场规模估计为 21 亿美元，中国市场预计复合年增长率为 7.1%

美国转录组学技术市场规模预计在2024年达到21亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到19亿美元，在2024-2030年的分析期间内，复合年增长率为7.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为6.4%和6.3%。在欧洲，预计德国市场的复合年增长率约为6.0%。

全球「转录组学技术」市场—主要趋势与驱动因素摘要

为什么转录组学对于精准医疗时代至关重要？

转录组学是对基因组产生的RNA转录本的综合研究，它正迅速发展成为现代生物医学研究的基石，尤其是在日益扩张的精准医疗领域。透过分析不同组织、细胞类型和疾病状态下基因的动态表达，转录组学为细胞功能和病理提供了前所未有的见解。这种能力改变了科学家诊断疾病、识别生物标记和对患者进行分层以进行标靶治疗。 COVID-19大流行极大地加速了全世界对体学技术（包括转录组学）的认识，因为研究人员利用RNA分析来追踪病毒进化和宿主反应。在肿瘤学领域，转录组分析已被广泛用于了解肿瘤异质性和识别新的药物标靶。此外，罕见疾病研究在转录组分析方面取得了突破，从而可以更好地分类和理解单表型疾病。随着生物製药公司增加对个人化治疗的投资，转录组学在药物发现、毒理基因组学和临床试验优化中的作用正在急剧扩大。这种日益增长的临床和商业性相关性清楚地表明了为什么转录组学不再只是一种研究工具，而且越来越多地被视为下一代诊断和治疗的基础。

次世代定序仪和生物资讯学如何推动转录组学的创新？

转录组学的爆炸性成长得益于新一代定序 (NGS)、单细胞 RNA 定序 (scRNA-seq) 和高通量微阵列平台的技术突破。这些工具使研究人员能够以前所未有的分辨率和规模获取基因表现数据，揭示基因活动的整体趋势和细微变化。单细胞技术尤其彻底改变了该领域，它能够在单一细胞层级绘製转录组图，揭示先前隐藏的细胞亚型和疾病机制。同时，长读长定序技术的进步正在解决转录异构体检测和可变剪接分析的限制。然而，转录组学研究产生的大量资料需要先进的计算工具来管理、解释和视觉化结果。人工智慧和机器学习模型正越来越多地被应用于识别复杂模式、预测基因功能和自动分类细胞类型。云端基础的生物资讯平台和开放原始码资料库正在使全球研究人员更容易使用这些强大的工具。湿实验室创新与干实验室分析的结合不仅扩大了转录组学的效用，而且加快了多个治疗领域的发现时间。

转录组学技术能否弥合基因组学和功能生物学之间的差距？

基因组学揭示了生命的蓝图，而转录组学则提供了该蓝图在各种生物和环境条件下如何被解读的即时简介。这种差异使得转录组学对于功能基因组学和系统生物学至关重要，因为在这些领域，理解基因活动的背景至关重要。例如，在免疫学中，转录组分析用于监测免疫细胞活化，并识别与自体免疫疾病和疫苗反应相关的细胞激素特征。神经科学研究越来越依赖空间转录组学，这是一种绘製组织结构内基因表现图谱的新方法，用于探索脑细胞多样性和神经退化性疾病的路径。环境转录组学正在帮助生态学家评估动植物对气候变迁和污染的压力反应。农业基因组学也受益于转录组学，从而能够培育出产量更高、抗逆性和抗病虫害的作物。此类跨学科应用反映出一种日益增长的共识，即转录组学弥合了静态基因组数据与动态细胞功能之间的关键差距，不仅在医疗保健领域，而且在更广泛的生命科学生态系统中都至关重要。

转录组学技术市场的成长受到多种因素的推动…

转录组学技术市场的成长受到与研究需求、技术成熟度和最终用户扩展相关的若干因素的驱动。一个主要的催化剂是个人化医疗的兴起，其中 RNA 分析在识别患者特异性疾病途径和定制治疗方面发挥核心作用。政府和私人投资者增加对生命科学研究的资助，支持肿瘤学、感染疾病和神经生物学等领域的大规模转录组学研究。单细胞定序、空间转录组学和高通量自动化等技术进步使得能够以更低的成本进行更广泛、更详细的转录组学分析。製药公司正在将转录组学纳入其药物开发平臺，以降低化合物风险、发现脱靶效应并加快监管核准流程。临床实验室已开始采用转录组学面板作为诊断工具，尤其是在肿瘤学和罕见疾病检测中。此外，生物资讯学平台和用户友好的数据视觉化工具的广泛普及正在使转录组学变得民主化，并增强了学术界和工业界研究人员的能力。法律规范也在逐步调整，以适应基于转录组学的诊断方法，为商业化开闢了新的途径。这些因素共同作用，将转录组学从一种小众的科学方法转变为生物医学和生命科学领域创新的重要引擎。

部分

类型（耗材、仪器、软体、服务）、技术（微阵列、qPCR、定序技术）、应用（药物研发、诊断/疾病分析、其他应用）

调查企业范例（共32家企业）

  • 10x Genomics
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company（BD）
  • Bio-Rad Laboratories, Inc.
  • BGI Genomics
  • Danaher Corporation
  • Fluidigm Corporation
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Illumina, Inc.
  • LC Sciences, LLC
  • Merck KGaA
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • Promega Corporation
  • Qiagen NV
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vizgen, Inc.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP35901

Global Transcriptomics Technologies Market to Reach US$12.0 Billion by 2030

The global market for Transcriptomics Technologies estimated at US$7.9 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Transcriptomics Consumables, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Transcriptomics Instruments segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 7.1% CAGR

The Transcriptomics Technologies market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global "Transcriptomics Technologies" Market - Key Trends & Drivers Summarized

Why Is Transcriptomics Taking Center Stage in the Era of Precision Medicine?

Transcriptomics-the comprehensive study of RNA transcripts produced by the genome-has rapidly evolved into a cornerstone of modern biomedical research, especially within the expanding domain of precision medicine. By analyzing the dynamic expression of genes in different tissues, cell types, and disease states, transcriptomics offers unparalleled insights into cellular function and pathology. This capability has transformed how scientists diagnose diseases, identify biomarkers, and stratify patients for targeted therapies. The COVID-19 pandemic notably accelerated global awareness of omics technologies, including transcriptomics, as researchers used RNA profiling to track viral evolution and host responses. In oncology, transcriptome sequencing is now frequently used to understand tumor heterogeneity and identify novel drug targets. Additionally, rare disease research has seen breakthroughs through transcriptomic analysis, allowing for better classification and understanding of monogenic disorders. As biopharma companies deepen their investment in personalized therapeutics, the role of transcriptomics in drug discovery, toxicogenomics, and clinical trial optimization has expanded dramatically. This growing clinical and commercial relevance underscores why transcriptomics technologies are now regarded not just as research tools but as foundational to the next generation of diagnostics and therapeutics.

How Are Next-Gen Sequencing and Bioinformatics Powering Transcriptomics Innovation?

The explosive growth of transcriptomics owes much to technological breakthroughs in next-generation sequencing (NGS), single-cell RNA sequencing (scRNA-seq), and high-throughput microarray platforms. These tools enable researchers to capture gene expression data at unprecedented resolution and scale, revealing both broad trends and subtle variations in gene activity. Single-cell techniques, in particular, are revolutionizing the field by mapping transcriptomes at the level of individual cells, uncovering previously hidden cell subtypes and disease mechanisms. Meanwhile, advancements in long-read sequencing technologies are addressing limitations in transcript isoform detection and alternative splicing analysis. However, the deluge of data generated from transcriptomics studies requires sophisticated computational tools to manage, interpret, and visualize results. AI and machine learning models are increasingly applied to identify complex patterns, predict gene function, and automate the classification of cell types. Cloud-based bioinformatics platforms and open-source databases have made these powerful tools more accessible to researchers around the world. This integration of wet-lab innovation with dry-lab analytics is not only expanding the utility of transcriptomics but also accelerating the time-to-discovery across multiple therapeutic areas.

Can Transcriptomics Technologies Bridge the Gap Between Genomics and Functional Biology?

While genomics reveals the blueprint of life, transcriptomics provides real-time snapshots of how that blueprint is interpreted under varying biological and environmental conditions. This distinction has made transcriptomics essential for functional genomics and systems biology, where understanding gene activity in context is critical. In immunology, for example, transcriptomic profiling is being used to monitor immune cell activation and identify cytokine signatures associated with autoimmune diseases or vaccine responses. Neuroscience research is increasingly reliant on spatial transcriptomics-an emerging method that maps gene expression within tissue architecture-to explore brain cell diversity and neurodegenerative disease pathways. Environmental transcriptomics is another fast-emerging application, helping ecologists assess stress responses in plants and animals to climate change and pollution. Agricultural genomics also benefits from transcriptomics, enabling the breeding of crops with improved yield, stress tolerance, and resistance to pests. These cross-sector applications reflect a growing consensus that transcriptomics bridges the critical gap between static genomic data and dynamic cellular function, making it indispensable not just in healthcare, but across the broader life sciences ecosystem.

The Growth in the Transcriptomics Technologies Market Is Driven by Several Factors…

The growth in the transcriptomics technologies market is driven by several factors linked to research demand, technological maturity, and end-user expansion. A key catalyst is the rise of personalized medicine, where RNA profiling plays a central role in identifying patient-specific disease pathways and tailoring treatments. Increased funding for life sciences research-by both governments and private investors-is supporting large-scale transcriptomics studies in areas like oncology, infectious disease, and neurobiology. Technological advancements such as single-cell sequencing, spatial transcriptomics, and high-throughput automation are enabling broader, more detailed transcriptomic analyses at lower costs. Pharmaceutical companies are incorporating transcriptomics into drug development pipelines to de-risk compounds, understand off-target effects, and accelerate regulatory approval processes. Clinical laboratories are beginning to adopt transcriptomic panels as diagnostic tools, particularly in oncology and rare disease testing. Furthermore, the proliferation of bioinformatics platforms and user-friendly data visualization tools has democratized transcriptomics, empowering researchers in academia and industry alike. Regulatory frameworks are gradually adapting to accommodate transcriptomics-based diagnostics, opening new pathways for commercialization. Collectively, these drivers are transforming transcriptomics from a niche scientific method into a vital engine of biomedical and life science innovation.

SCOPE OF STUDY:

The report analyzes the Transcriptomics Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Consumables, Instruments, Software, Services); Technology (Microarrays, qPCR, Sequencing Technology); Application (Drug Discovery, Diagnostics & Disease Profiling, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • 10x Genomics
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • BGI Genomics
  • Danaher Corporation
  • Fluidigm Corporation
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Illumina, Inc.
  • LC Sciences, LLC
  • Merck KGaA
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • Promega Corporation
  • Qiagen N.V.
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vizgen, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transcriptomics Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Precision Medicine and Personalized Therapy Drives Transcriptomics Adoption
    • Rapid Advances in RNA Sequencing Technologies Throw the Spotlight on Omics Integration
    • Expanding Applications in Oncology and Rare Disease Research Propel Market Growth
    • Increasing Role of Transcriptomics in Drug Discovery and Target Validation Spurs Demand
    • Expansion of Single-Cell Analysis Capabilities Accelerates Innovation and Research Outcomes
    • Collaborations Between Biotech Companies and Research Institutions Expand Commercialization Scope
    • Growing Utility of Non-Coding RNA Analysis Opens Up New Revenue Streams
    • Development of Multi-Omics Platforms Sustains Demand for High-Throughput Transcriptomics
    • Accelerating Trend Toward Predictive Diagnostics Expands the Addressable Market
    • Rising Use of Transcriptomics in Agriculture and Environmental Science Broadens Market Applications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transcriptomics Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Transcriptomics Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics & Disease Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Diagnostics & Disease Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Microarrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for qPCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • JAPAN
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • CHINA
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • EUROPE
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Transcriptomics Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • FRANCE
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • GERMANY
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • UNITED KINGDOM
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030

IV. COMPETITION